Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Oct;33(10):725-736.
doi: 10.1007/s40266-016-0405-y.

Effects of Renal Impairment on Steady-State Plasma Concentrations of Rivastigmine: A Population Pharmacokinetic Analysis of Capsule and Patch Formulations in Patients with Alzheimer's Disease

Gilbert Lefèvre  1 , Francesca Callegari  2 , Sandro Gsteiger  2 , Yuan Xiong  3
Affiliations
Clinical Trial

Effects of Renal Impairment on Steady-State Plasma Concentrations of Rivastigmine: A Population Pharmacokinetic Analysis of Capsule and Patch Formulations in Patients with Alzheimer's Disease

Gilbert Lefèvre et al. Drugs Aging. 2016 Oct.

Abstract

Introduction: The glomerular filtration rate (GFR), a measure of renal function, decreases by approximately 10 mL/min every 10 years after the age of 40 years, which could lead to the accumulation of drugs and/or renal toxicity. Pharmacokinetic studies of drugs excreted both renally and non-renally are desirable in patients with impaired renal function, defined by parameters including estimated GFR (eGFR) and creatinine clearance (CLCR).

Objective: We describe here a population pharmacokinetic analysis of the possible effects of renal impairment on steady-state plasma concentrations of rivastigmine and its metabolite NAP226-90 after rivastigmine patch (5 cm2 [4.6 mg/24 h], 10 cm2 [9.5 mg/24 h], 15 cm2 [13.3 mg/24 h], and 20 cm2 [17.4 mg/24 h]) and capsule (1.5, 3, 4.5, and 6 mg/12 h) treatment in patients with Alzheimer's disease.

Methods: The data used to conduct the current pharmacokinetic analysis were obtained from the pivotal phase III, 24-week, multicenter, randomized, double-blind, placebo- and active-controlled, parallel-group study (IDEAL). One blood sample was collected from each patient at steady-state to measure plasma concentrations of rivastigmine and NAP226-90 using a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. The steady-state plasma concentrations of rivastigmine and NAP226-90 were plotted against CLCR and eGFR data, and boxplots were constructed after stratification by renal function.

Results: The two groups (mild/no renal impairment vs. moderate/severe/end-stage renal impairment) showed comparable demographic covariates for all patch sizes and capsule doses. No correlation was observed between CLCR or eGFR and plasma concentrations of rivastigmine or NAP226-90. Boxplots of concentrations of rivastigmine or NAP226-90 for each dose largely overlapped for patch and capsule. Additionally, model-based estimates of plasma concentrations adjusted for body weight yielded similar results.

Conclusion: The results of this study show that renal function does not affect rivastigmine or NAP226-90 steady-state plasma concentrations, and no dose adjustment in patients with renal impairment is required. CLINICALTRIALS.GOV: NCT00099242.

PubMed Disclaimer

Conflict of interest statement

Compliance with Ethical StandardsFundingThis study was funded by Novartis Pharma AG, Basel, Switzerland.Disclosure of Potential Conflicts of interestGilbert Lefèvre and Francesca Callegari are employees of Novartis and as such may be eligible for Novartis stock and stock options. Sandro Gsteiger and Yuan Xiong were employees of Novartis at the time of the research and analysis and as such may have been eligible for Novartis stock and stock options. None of the authors are Fellows of the American College of Clinical Pharmacology (FCP).Research Involving Human ParticipantsThe protocol, informed consent form, any amendments, and other information given to patients and caregivers were reviewed by an Institutional Review Board or Independent Ethics Committee for each center. The study was conducted according to the ethical principles of the Declaration of Helsinki, as revised in 2000.Informed ConsentInformed consent was obtained from all individual participants included in the study.

Figures

Fig. 1
Fig. 1
Rivastigmine and NAP226-90 steady-state plasma concentrations stratified by baseline renal impairment as measured by creatinine clearance (CLCR) and estimated glomerular filtration rate (eGFR) following patch application
Fig. 2
Fig. 2
Rivastigmine and NAP226-90 steady-state plasma concentrations stratified by baseline renal impairment as measured by creatinine clearance (CLCR) and estimated glomerular filtration rate (eGFR) following capsule administration
Fig. 3
Fig. 3
Rivastigmine and NAP226-90 steady-state plasma concentrations versus baseline creatinine clearance and estimated glomerular filtration rate following patch application
Fig. 4
Fig. 4
Rivastigmine and NAP226-90 steady-state plasma concentrations versus baseline creatinine clearance and estimated glomerular filtration rate following capsule administration
See this image and copyright information in PMC

References

    1. Bird TD. Genetic aspects of Alzheimer disease. Genet Med. 2008;10:231–239. doi: 10.1097/GIM.0b013e31816b64dc. - DOI - PMC - PubMed
    1. Rao AT, Degnan AJ, Levy LM. Genetics of Alzheimer disease. AJNR Am J Neuroradiol. 2014;35:457–458. doi: 10.3174/ajnr.A3545. - DOI - PMC - PubMed
    1. Bell JS, Blacker N, Leblanc VT, Alderman CP, Phillips A, Rowett D, et al. Prescribing for older people with chronic renal impairment. Aust Fam Physician. 2013;42:24–28. - PubMed
    1. Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol. 1976;31:155–163. doi: 10.1093/geronj/31.2.155. - DOI - PubMed
    1. Glassock RJ. The GFR decline with aging: a sign of normal senescence, not disease. Nephrol Times. 2009;9:6–8. doi: 10.1097/01.NEP.0000361312.27730.cc. - DOI

Publication types

MeSH terms

Associated data